Literature DB >> 16449677

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.

Craig C Earle1, Deborah Schrag, Bridget A Neville, K Robin Yabroff, Marie Topor, Angela Fahey, Edward L Trimble, Diane C Bodurka, Robert E Bristow, Michael Carney, Joan L Warren.   

Abstract

BACKGROUND: For many diseases, specialized care (i.e., care rendered by a specialist) has been associated with superior-quality care (i.e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients.
METHODS: We analyzed the Medicare claims, by physician specialty, of all women aged 65 years or older who underwent surgery for pathologically confirmed invasive epithelial ovarian cancer between January 1, 1992, and December 31, 1999, while living in an area monitored by the Surveillance, Epidemiology, and End Results (SEER) program to assess important care processes (i.e., the appropriate extent of surgery and use of adjuvant chemotherapy) and outcomes (i.e., surgical complications, ostomy rates, and survival). All statistical tests were two-sided.
RESULTS: Among 3067 ovarian cancer patients who underwent surgery, 1017 patients (33%) were treated by a gynecologic oncologist, 1377 patients (45%) by a general gynecologist, and 673 patients (22%) by a general surgeon. Among patients with stage I or II disease, those treated by a gynecologic oncologist (60%) were more likely to undergo lymph node dissection than those treated by a general gynecologist (36%) or a general surgeon (16%). Patients with stage III or IV disease were more likely to undergo a debulking procedure if the initial surgery was performed by a gynecologic oncologist (58%) than by a general gynecologist (51%) or a general surgeon (40%; P < .001) and were more likely to receive postoperative chemotherapy when operated on by a gynecologic oncologist (79%) or a general gynecologist (76%) than by a general surgeon (62%, P < .001). Survival among patients operated on by gynecologic oncologists (hazard ratio [HR] of death from any cause = 0.85, 95% confidence interval [CI] = 0.76 to 0.95) or general gynecologists (HR = 0.86, 95% CI = 0.78 to 0.96) was better than that among patients operated on by general surgeons.
CONCLUSIONS: Ovarian cancer patients treated by gynecologic oncologists had marginally better outcomes than those treated by general gynecologists and clearly superior outcomes compared with patients treated by general surgeons.

Entities:  

Mesh:

Year:  2006        PMID: 16449677     DOI: 10.1093/jnci/djj019

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  88 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  A national initiative for women and healthcare providers: CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer campaign.

Authors:  Sun Hee Rim; Lindsey Polonec; Sherri L Stewart; Cynthia A Gelb
Journal:  J Womens Health (Larchmt)       Date:  2011-09-20       Impact factor: 2.681

3.  Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Authors:  Yan Zhang; Chunxia Qiao; Lian Li; Xuye Zhao; Yali Li
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

4.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Authors:  Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2010-03-24       Impact factor: 5.482

5.  Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-04-15       Impact factor: 5.482

6.  Enhancement of identifying cancer specialists through the linkage of Medicare claims to additional sources of physician specialty.

Authors:  Lori A Pollack; Walter Adamache; Christie R Eheman; A Blythe Ryerson; Lisa C Richardson
Journal:  Health Serv Res       Date:  2008-12-15       Impact factor: 3.402

Review 7.  Operative management of primary epithelial ovarian cancer.

Authors:  Mario M Leitao; Dennis S Chi
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

8.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

9.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

10.  Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.

Authors:  Sean C Dowdy; Ralitsa T Loewen; Giovanni Aletti; Simone S Feitoza; William Cliby
Journal:  Gynecol Oncol       Date:  2008-04-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.